CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
April 12, 2017 05:09 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and LEATHERHEAD, United Kingdom, April 12, 2017 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA:UR9) (OTC:CLVLY) today announced that it had reached agreement...
Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
January 12, 2017 08:05 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline
July 12, 2016 16:12 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new...
US FDA pathway opens to SCENESSE® following Fast Track designation for treatment of EPP
July 06, 2016 08:00 ET
|
Clinuvel Pharmaceuticals Limited
FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPPNDA filing allowed on a rolling basisFDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment ...
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
November 18, 2014 05:44 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
...
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
November 17, 2014 08:01 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated
...
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
February 11, 2014 09:27 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...
China Investing Billions in Bid to Catch Up With Western Pharma
July 11, 2013 07:30 ET
|
Lux Research
BOSTON, MA--(Marketwired - Jul 11, 2013) - China's biomedical sector is rapidly transforming itself from a manufacturing base to an innovation hub, investing billions of dollars and setting up...
International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5
June 07, 2012 07:01 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today that it has initiated the international patent process for protection of the Company's peptide vaccine...
International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
June 07, 2012 07:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
The new patent filed 6 June aims to strengthen the Company's general protection of its...